Speaker: Date: Topic
Richard S. Beaser, MD
Jan. 18, 2017
Advancing to Insulin Replacement Therapy: When, Why, and How?
Director of Medical Education and Committee Members have indicated they have no relevant financial interests or relationships to disclose. Faculty has indicated no relevant financial interests or relationships to disclose.
Responsibility for Content
The PowerPoint presentation, Take-Away points, Objectives, Link, and Abstract links were sent by Medical Library Services and the CME Committee.
Diane E. Young, Information Specialist
Take-Away Points of the Presentation
1. When treating Type 2 diabetes with insulin, treatment goals, selection from various program design options, and monitoring recommendations must be individualized for patient physiologic needs, self-care abilities, and safety.
2. Sequential advancement of insulin treatment designs is an important part of that individualized approach to therapy.
3. Basal-bolus regimens require more injections but provide better insulin coverage and glycemic control.
4. Don't delay initiation of insulin: Self-assess office capabilities in the context of insulin treatment support.
Objectives of the Presentation
Participants should be able to:
- Identify clinical indications for initiation of basal insulin for type 2 diabetes based on the natural history of type 2 diabetes.
- Describe options for advancing insulin therapy for type 2 diabetes beyond basal-only, and the rationale for use of each.
- Discuss indications for use of a physiologic insulin program using the "basal/bolus" construct, various means to design such a program, and how such a program might be implemented in a clinical practice setting.